Michael Levine
Pediatric Endocrinology · Philadelphia, PANPI 1811033962
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $96,415 of the $128,114 with a category attached, or 75.3%. It is spread thinly across 19 manufacturers, the largest accounting for just 23.5%. Reporting peaked in 2019 at $35,575 and has fallen 56.7% since, to $15,397 in 2025. Among pediatric endocrinology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 72 payments — averaging $1779.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- American Regent$30K
- Shire North American Group Inc$16K
- AstraZeneca$13K
- Immedica Pharma US, Inc.$10K
- Takeda Pharmaceuticals U.S.A., Inc.$9K
- Kyowa Kirin, Inc.$9K
- plus $40K from 13 others
Across 173 payments — averaging $3164.41 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ultragenyx Pharmaceutical Inc.$331K
- AstraZeneca$115K
- Takeda Pharmaceuticals U.S.A., Inc.$54K
- Shire North American Group Inc$47K
What the payments were for
- Consulting fees$96,41575%
- Speaking & faculty fees$17,24913%
- Travel & lodging$13,15410%
- Food & beverage$1,2401%
- Education$560%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| American Regent | 5 | $30,119 |
| Shire North American Group Inc | 13 | $16,229 |
| AstraZeneca | 7 | $13,356 |
| Immedica Pharma US, Inc. | 1 | $10,150 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $9,290 |
| Kyowa Kirin, Inc. | 4 | $8,810 |
| Pfizer | 3 | $8,500 |
| Pharmacosmos Therapeutics Inc. | 2 | $5,642 |
| Ascendis Pharma Endocrinology Inc | 2 | $5,330 |
| Biomarin Pharmaceutical Inc. | 15 | $5,103 |
| Merck | 1 | $4,800 |
| CSL Behring | 1 | $4,200 |
| Day One Biopharmaceuticals | 1 | $3,500 |
| Mirum Pharmaceuticals, Inc. | 2 | $1,400 |
| Novo Nordisk Health Care AG | 1 | $1,000 |
| Kyowa Kirin Co., Ltd | 1 | $475 |
| Next Science LLC | 2 | $155 |
| Corcept Therapeutics | 2 | $34 |
| Acella Pharmaceuticals, LLC | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INJECTAFER$30,119
- NATPARA (PARATHYROID HORMONE)$22,178
- Monoferric$5,642
- SKYTROFA$5,330
- HEMGENIX$4,200
- OJEMDA$3,500
How this compares
$128,114 in reported general payments places this provider in the 95th percentile of 80 pediatric endocrinology providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CrysvitaBurosumab-Twza | 26 | $1,052,125 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Kyowa Kirin, Inc.Crysvita | $8,810 | $1,052,12526 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 80 pediatric endocrinology providers in Pennsylvania.
Other pediatric endocrinology in Philadelphia
- Craig AlterPhiladelphia$102K
- Judith RossPhiladelphia$75K
- Julia CrowleyPhiladelphia$75K
- Steven WilliPhiladelphia$34K
- Andrew BauerPhiladelphia$34K
- David WeberPhiladelphia$24K
- Diva DeleonPhiladelphia$21K
- Andrew CalabriaPhiladelphia$20K
- Maria VogiatziPhiladelphia$16K
- Adda GrimbergPhiladelphia$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.